Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding.

Acta obstetricia et gynecologica Scandinavica (2014-06-11)
Pirkko Peuranpää, Satu Heliövaara-Peippo, Ian Fraser, Jorma Paavonen, Ritva Hurskainen
RESUMO

To assess the impact of anemia and iron deficiency on health-related quality of life (HRQoL) in women treated for heavy menstrual bleeding (HMB). Secondary analysis of a randomized controlled trial. Five university hospitals in Finland. A total of 236 women referred for HMB. Women were randomized to treatment with hysterectomy or a levonorgestrel-releasing intrauterine system. We defined groups based on women's pretreatment hemoglobin [hemoglobin <120 g/L (anemic) vs. hemoglobin ≥120 g/L (nonanemic)] and serum ferritin (ferritin <15 μg/L vs. ≥15 μg/L) concentrations. HRQoL was compared between groups at baseline, 6 and 12 months after treatment. Hemoglobin and ferritin were followed for 5 years. HRQoL was measured by the RAND 36-item health survey (RAND-36), 5-Dimensional EuroQol and two questionnaires of mental wellbeing. At baseline, 63 women (27%) were anemic and 140 (60%) were severely iron deficient (ferritin <15 μg/L). Only 8% of the anemic women had taken iron supplementation. Twelve months after treatment hemoglobin had increased in both hemoglobin groups, but was still significantly lower (p < 0.001) in initially anemic women (128 g/L) compared with nonanemic women (136 g/L). Twelve months after treatment three domain scores of RAND-36 increased more (energy, p = 0.002; physical functioning, p = 0.04; social functioning, p = 0.05), and anxiety (p = 0.02) and depression scores (p = 0.002) decreased more in anemic compared with nonanemic women. Serum ferritin took 5 years to reach normal levels. Improved HRQoL after treatment of HMB is associated with correction of anemia. Clinicians should actively screen for anemia in women with HMB and emphasize early iron substitution as an integral part of treatment.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Iron, ≥99%, reduced, powder (fine)
Sigma-Aldrich
Ferritin from equine spleen, Type I, saline solution
Sigma-Aldrich
Iron, powder, −325 mesh, 97%
Sigma-Aldrich
Carbonyl iron, ≥97% Fe basis
Sigma-Aldrich
Iron, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
Iron, nanopowder, 35-45 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
Iron, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
Iron, chips, 99.98% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Ferritin from human liver, Type IV, 10 μg/mL
Sigma-Aldrich
Iron, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Ferritin from human spleen, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
Sigma-Aldrich
Iron, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Supelco
D(−)-Norgestrel, analytical standard
Sigma-Aldrich
Iron, carbon coated magnetic, nanopowder, 25 nm avg. part. size, 99.5% trace metals basis
Levonorgestrel, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Iron, wire, diam. 0.5 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Iron, rod, diam. 6.3 mm, 99.98% trace metals basis
Iron, IRMM®, certified reference material, 0.5 mm wire
Iron, foil, 300x300mm, thickness 0.1mm, hard, 99.5%
Iron, foil, 0.2m coil, thickness 0.5mm, coil width 49mm, armco« soft ingot 99.8+%
Levonorgestrel for system suitability 2, European Pharmacopoeia (EP) Reference Standard
Iron, wire reel, 1m, diameter 0.025mm, as drawn, 99.99+%
Iron, wire reel, 20m, diameter 0.125mm, hard, 99.5%
Iron, foil, 10mm disks, thickness 0.01mm, 99.85%
Iron, foil, 10mm disks, thickness 0.01mm, 99.99+%
Iron, foil, 10mm disks, thickness 0.020mm, 99.85%
Iron, foil, 10mm disks, thickness 0.025mm, as rolled, 99.99+%
Iron, foil, 10mm disks, thickness 0.025mm, hard, 99.5%
Iron, foil, 10mm disks, thickness 0.038mm, hard, 99.5%

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.